Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway - PubMed (original) (raw)

Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway

Takahiro Seki et al. J Control Release. 2011.

Abstract

Tumour Necrosis Factor alpha (TNF) is a pleiotropic pro-inflammatory cytokine with known vascular permeabilising activity. It is employed during isolated limb perfusion to enhance delivery of chemotherapeutic drugs into tumour tissue. The use of conditionally-replicating lytic viruses, so called 'oncolytic virotherapy', provides a new approach to cancer treatment that is currently limited by the low efficiency of extravasation of viral particles into tumours. We report here evidence that TNF significantly enhances the delivery of virus particles through the endothelial layer to allow access to tumour cells both in vitro and in vivo. Intravenous administration of TNF resulted in a 3- to 6-fold increase in EL4 tumour uptake of Evans Blue/Albumin, adenovirus and long-circulating polymer coated adenovirus. Interestingly, endothelial permeabilisation could be suppressed in vitro and in vivo by Y-27632, a Rho kinase inhibitor, without inhibiting viral infection. These data indicate that TNF can enhance the delivery of virus particles into tumours through a Rho A/Rho kinase dependent mechanism and may be a valuable strategy for increasing the delivery of oncolytic viruses and other therapeutic agents.

PubMed Disclaimer

Cited by

Rho A/ROCK1 signaling-mediated metabolic reprogramming of valvular interstitial cells toward Warburg effect accelerates aortic valve calcification via AMPK/RUNX2 axis.
Liu H, Yin H, Wang Z, Yuan Q, Xu F, Chen Y, Li C. Liu H, et al. Cell Death Dis. 2023 Feb 11;14(2):108. doi: 10.1038/s41419-023-05642-1. Cell Death Dis. 2023. PMID: 36774349 Free PMC article.
Enhanced Permeability and Retention Effect as a Ubiquitous and Epoch-Making Phenomenon for the Selective Drug Targeting of Solid Tumors.
Islam W, Niidome T, Sawa T. Islam W, et al. J Pers Med. 2022 Nov 28;12(12):1964. doi: 10.3390/jpm12121964. J Pers Med. 2022. PMID: 36556185 Free PMC article. Review.
Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect.
Huang D, Sun L, Huang L, Chen Y. Huang D, et al. J Pers Med. 2021 Feb 14;11(2):124. doi: 10.3390/jpm11020124. J Pers Med. 2021. PMID: 33672813 Free PMC article. Review.
The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy.
Yang Q, Guo N, Zhou Y, Chen J, Wei Q, Han M. Yang Q, et al. Acta Pharm Sin B. 2020 Nov;10(11):2156-2170. doi: 10.1016/j.apsb.2020.04.004. Epub 2020 Apr 19. Acta Pharm Sin B. 2020. PMID: 33304783 Free PMC article. Review.
Blood-Brain Barrier, Blood-Brain Tumor Barrier, and Fluorescence-Guided Neurosurgical Oncology: Delivering Optical Labels to Brain Tumors.
Belykh E, Shaffer KV, Lin C, Byvaltsev VA, Preul MC, Chen L. Belykh E, et al. Front Oncol. 2020 Jun 5;10:739. doi: 10.3389/fonc.2020.00739. eCollection 2020. Front Oncol. 2020. PMID: 32582530 Free PMC article. Review.

Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway - PubMed (original) (raw)